CORPORATE You heard it here first. ALL CORPORATE INVESTORS Our news BRINGING YOU THE LATEST! Corporate Phase 3 data of mdc-IRM first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia Corporate - Investors 15 November 2021 Phase 3 data of mdc-IRM, first product based on MedinCell’s […] Read full story MedinCell: mdc-IRM’s Phase 3 data to be presented for the first time by Teva at Psych Congress 2021 Corporate - Investors 21 October 2021 Read full story Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia Corporate - Investors 31 August 2021 Read full story Participation terms in the MedinCell Combined General Meeting Corporate - Investors 4 August 2021 Read full story MedinCell announces the availability of its 2020/2021 Universal Registration Document including the Annual Financial Report Corporate 28 July 2021 Read full story MedinCell announces fiscal year consolidated results Corporate 16 June 2021 Read full story MedinCell’s Long-Acting Injectable to fight Malaria ready to enter Regulatory Development Corporate 14 June 2021 Read full story Clinical trial conducted by MedinCell confirms the safety of continuous administration of ivermectin Corporate 19 April 2021 Read full story Posts navigation 1 2 … 4 Subject Partnership Development Scientific collaboration Press and communication Administration People Stay tuned, leave your email I read and accept the privacy policy HOME WHO ARE WE PRODUCT IMPACT NETWORK NEWS INVESTORS CAREERS Copyright © 2021 MedinCell. All rights reserved. | Legal | Privacy | #BetterMedicineForAll | #ImpactHealth | WHO ARE WE PRODUCT IMPACT NETWORK NEWS INVESTORS CAREERS